The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.

Journal article

AIM: To assess the treatment effects of rituximab in a population of patients with myasthenia gravis and Lambert-Eaton myasthenic syndrome. METHODS: Data on all treated patients in the UK were collected from referring physicians, with full case ascertainment and follow-up. RESULTS: Since 2004, 10 patients with generalised myasthenia gravis (three of whom were positive for muscle-specific tyrosine kinase (MuSK) antibodies) and two patients with Lambert-Eaton myasthenic syndrome (LEMS) were tr...

Expand abstract

Authors: Maddison, P; McConville, J; Farrugia, M; Davies, N; Rose, M

• Journal: Journal of neurology, neurosurgery, and psychiatry
• Volume: 82
• Issue: 6
• Pages: 671-673
• Publication date: 2011-06-01
• DOI: 10.1136/jnnp.2009.197632
• EISSN: 1468-330X
• ISSN: 0022-3050
• Language: English
• Keywords: Protein-Tyrosine Kinases; Myasthenia Gravis; Receptors, Cholinergic; Child; Adolescent; Child, Preschool; Humans; Adult; Antibodies, Monoclonal, Murine-Derived; Male; Immunologic Factors; Lambert-Eaton Myasthenic Syndrome; Retrospective Studies; Middle Aged; Receptor Protein-Tyrosine Kinases; Female